RNeasy Mini Kit

High-quality total RNA in minutes.

Investigator 24plex QS Kit

Multiplex amplification for human ID, with CODIS and European standard markers.

QIAsphere

Monitor and manage your QIAsphere-ready instruments from anywhere, using any mobile device.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

QIAGEN Clinical Insight (QCI) Interpret

Transparent, evidence-based NGS interpretation and reporting.

Find out more

QIAGENbioinformatics.com

COVID-19 testing and research

Up to date protocols and list of COVID-19 testing and research solutions.

RNeasy Mini Kit

High-quality total RNA in minutes.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

QuantiFERON-TB Gold Plus

Detect TB infection with confidence.

QIAGEN Clinical Insight (QCI) Interpret

Transparent, evidence-based NGS interpretation and reporting.

Key Figures

Home  >  Investor Relations  >  At a Glance  >  Key Figures
Years ended December 31
$1,000 except per share data 2022 2021 2020 2019 2018
Result
Net sales 2,141,518 2,251,657 1,870,346 1,526,424 1,501,848
Operating income (loss) 531,460 630,084 386,431 (26,136) 266,581
Net income (loss) 423,211 512,599 359,188 (41,455) 190,380
Basic earnings (loss) per share (EPS) 1.86 2.25 1.57 (0.18) 0.84
Diluted earnings (loss) per share (EPS) 1.84 2.21 1.53 (0.18) 0.82
Number of shares (in thousands)
Common shares used to compute basic earnings per share1 227,577 227,983 228,427 226,777 226,640
Common shares used to compute diluted earnings per share2 230,136 232,034 234,214 226,777 233,456
Cash flow
Cash flow from operations 715,264 639,001 457,806 330,843 359,496
Capital expenditures for property, plant and equipment 129,224 189,904 132,787 117,950 109,773
Free cash flow3 586,040 449,097 325,019 212,893 249,723

As of December 31

Balance sheet
Total assets 6,287,735 6,146,954 5,912,530 5,235,616 5,748,332
Cash, cash equivalents and restricted cash 730,669 880,516 597,984 629,390 1,159,079
Total long-term liabilities, including current portion 2,236,153 2,380,560 2,542,144 2,032,924 2,644,373
Total equity 3,466,611 3,096,550 2,797,839 2,536,591 2,634,970

Please visit Financial Reports for more information.

1Weighted average number of common shares used to compute basic earnings per common share

2Weighted average number of common shares used to compute diluted earnings per common share

3Free cash flow is calculated from cash provided by operations reduced by purchases of property, plant and equipment